» Articles » PMID: 17622571

Inhibition of HMGcoA Reductase by Atorvastatin Prevents and Reverses MYC-induced Lymphomagenesis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2007 Jul 12
PMID 17622571
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Statins are a class of drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMGcoA) reductase, a critical enzyme in the mevalonate pathway. Several reports document that statins may prevent different human cancers. However, whether or not statins can prevent cancer is controversial due to discordant results. One possible explanation for these conflicting conclusions is that only some tumors or specific statins may be effective. Here, we demonstrate in an in vivo transgenic model in which atorvastatin reverses and prevents the onset of MYC-induced lymphomagenesis, but fails to reverse or prevent tumorigenesis in the presence of constitutively activated K-Ras (G12D). Using phosphoprotein fluorescence-activated cell sorter (FACS) analysis, atorvastatin treatment was found to result in the inactivation of the Ras and ERK1/2 signaling pathways associated with the dephosphorylation and inactivation of MYC. Correspondingly, tumors with a constitutively activated K-Ras (G12D) did not exhibit dephosphorylation of ERK1/2 and MYC. Atorvastatin's effects on MYC were specific to the inhibition of HMGcoA reductase, as treatment with mevalonate, the product of HMG-CoA reductase activity, abrogated these effects and inhibited the ability of atorvastatin to reverse or suppress tumorigenesis. Also, RNAi directed at HMGcoA reductase was sufficient to abrogate the neoplastic properties of MYC-induced tumors. Thus, atorvastatin, by inhibiting HMGcoA reductase, induces changes in phosphoprotein signaling that in turn prevent MYC-induced lymphomagenesis.

Citing Articles

The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells.

Yang J, Fang J, Singh S, Wells B, Wu Q, Janke L Res Sq. 2024; .

PMID: 38853928 PMC: 11160912. DOI: 10.21203/rs.3.rs-4390765/v1.


Targeting Dysregulated Lipid Metabolism in Cancer with Pharmacological Inhibitors.

Gupta A, Das D, Taneja R Cancers (Basel). 2024; 16(7).

PMID: 38610991 PMC: 11010992. DOI: 10.3390/cancers16071313.


A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.

Cash T, Jonus H, Tsvetkova M, Beumer J, Sadanand A, Lee J Pediatr Blood Cancer. 2023; 70(8):e30405.

PMID: 37158620 PMC: 11225565. DOI: 10.1002/pbc.30405.


The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.

Guerra B, Recio C, Aranda-Tavio H, Guerra-Rodriguez M, Garcia-Castellano J, Fernandez-Perez L Front Oncol. 2021; 11:626971.

PMID: 33718197 PMC: 7947625. DOI: 10.3389/fonc.2021.626971.


An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort.

Desai P, Wallace R, Anderson M, Howard B, Ray R, Wu C Cancer Med. 2018; 7(5):2121-2130.

PMID: 29608241 PMC: 5943473. DOI: 10.1002/cam4.1368.


References
1.
Carter P, Presta L, Gorman C, Ridgway J, Henner D, Wong W . Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992; 89(10):4285-9. PMC: 49066. DOI: 10.1073/pnas.89.10.4285. View

2.
Kato K, Cox A, Hisaka M, Graham S, Buss J, Der C . Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A. 1992; 89(14):6403-7. PMC: 49509. DOI: 10.1073/pnas.89.14.6403. View

3.
Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P . All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood. 1992; 80(9):2176-81. View

4.
Gupta S, Seth A, Davis R . Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc Natl Acad Sci U S A. 1993; 90(8):3216-20. PMC: 46270. DOI: 10.1073/pnas.90.8.3216. View

5.
Seth A, Gupta S, Davis R . Cell cycle regulation of the c-Myc transcriptional activation domain. Mol Cell Biol. 1993; 13(7):4125-36. PMC: 359962. DOI: 10.1128/mcb.13.7.4125-4136.1993. View